Synonyms: BOS 161721 | BOS161721
Compound class:
Antibody
Comment: Avizakimab (BOS161721; Boston Pharmaceuticals) is a humanized anti-IL-21 antibody that inhibits IL-21 bioactivity. It was developed for potential to treat systemic lupus erythematosus (SLE), an auotimmune condition in which IL-21 is implicated as a driving factor [3-5]. IL-21 has been explored as a therapeutic target in a range of autoimmune disease models (SLE, rheumatoid arthritis, type 1 diabetes and psoriasis). Peptide sequences for avizakimab are claimed in Boston Pharmaceuticals' patent US10022443B2 [1].
|
Classification ![]() |
|
Compound class | Antibody |
International Nonproprietary Names ![]() |
|
INN number | INN |
11148 | avizakimab |
Synonyms ![]() |
BOS 161721 | BOS161721 |
Database Links ![]() |
|
Specialist databases | |
IMGT/mAb-DB | 941 |
Other databases | |
GtoPdb PubChem SID | 473153858 |
Search PubMed clinical trials | avizakimab |
Search PubMed titles | avizakimab |
Search PubMed titles/abstracts | avizakimab |